返回 
加入收藏
格列美脲联合二甲双胍对初诊2型糖尿病患者糖脂代谢、胰岛功能及血清miR-126表达的影响
x
请在关注微信后，向客服人员索取文件
| 篇名： | 格列美脲联合二甲双胍对初诊2型糖尿病患者糖脂代谢、胰岛功能及血清miR-126表达的影响 |
| TITLE： | |
| 摘要： | 目的：探讨格列美脲联合二甲双胍对初诊2型糖尿病患者糖脂代谢、胰岛功能及血清微核糖核酸-126（miR-126）表达的影响。方法：选择2014年1月－2017年1月重庆市南川宏仁医院收治的初诊2 型糖尿病患者100例，按随机数字表法分为对照组和观察组，各50例。对照组患者给予盐酸二甲双胍缓释片（Ⅱ）起始剂量0.5 g，每日1次，连用12周后调整为0.5 g，每日2次，最大日剂量不超过1 g，进餐时或餐后服用；观察组患者在对照组治疗的基础上给予格列美脲片2 mg，每日1次，早餐时服用。两组患者均连续治疗至少24周。观察两组患者治疗前后血糖（空腹血糖、餐后2 h血糖、糖化血红蛋白）、血脂（总胆固醇、三酰甘油）、胰岛功能[空腹胰岛素（FINS）、餐后2 h胰岛素（2 hINS）、空腹C肽（FCP）、餐后2 hC肽（2 hCP）、胰岛素抵抗指数（HOMA-IR）]、血清miR-126表达水平及不良反应发生情况。结果：治疗前，两组患者血糖、血脂、胰岛功能、血清miR-126表达水平比较，差异均无统计学意义（P＞0.05）。治疗后，两组患者血糖、血脂水平、HOMA-IR均显著低于同组治疗前，且观察组血糖水平、HOMA-IR均显著低于对照组；两组患者FINS、2 h INS、FCP、2 hCP、血清miR-126表达水平均显著高于同组治疗前，且观察组显著高于对照组，差异均有统计学意义（P＜0.05）。两组患者治疗期间均未见明显不良反应发生。结论：格列美脲联合二甲双胍可显著改善初诊2 型糖尿病患者的糖脂代谢和胰岛功能，调节血清miR-126表达水平，且未增加不良反应的发生。 |
| ABSTRACT： | OBJECTIVE： To investigate the effects of glimepiride combined with metformin on glucose and lipid metabolism， islet function and serum miR-126 expression of newly diagnosed type 2 diabetes patients. METHODS： A total of 100 patients with newly diagnosed type 2 diabetes in Nanchuan Hongren Hospital of Chongqing during Jan. 2014-Jan. 2017 were divided into observation group and control group according to random numble table， with 50 cases in each group. Control group was given Metformin hydrochloride sustained-release tablets （Ⅱ） with initial dose of 0.5 g， once a day， adjusted to 0.5 g 12 weeks later， twice a day， maximal dose of 1 g at meal or after meal. Observation group was additionally given Glimepiride tablets 2 mg， once a day， at breakfast， on the basis of control group. Both group were treated at lasted for 24 weeks. The levels of blood glucose （FPG， 2 hPG， HbA1c）， blood lipid （TC， TG）， islet function （FINS， 2 hINS， FCP， 2 hCP， HOMA-IR）， serum miR-126 before and after treatment and the occurrence of ADR were observed in 2 groups. RESULTS： Before treatment， there was no statistical significance in the levels of blood glucose， blood lipid， islet function or serum miR-126 expression between 2 groups （P＞0.05）. After treatment， the levels of blood glucose， blood lipid and HOMA-IR in 2 groups were significantly lower than before treatment， and the levels of blood glucose and HOMA-IR in observation group were significantly lower than control group. The levels of FINS， 2 hINS， FCP and 2 hCP， serum miR-126 expression in 2 groups were significantly higher than before treatment， and the observation group was significantly higher than control group， with statistical significance（P＜0.05）. No obvious ADR was found in 2 groups during treatment. CONCLUSIONS： Glimepiride combined with metformin can significantly improve glucose and lipid metabolism， islet function， and regulate serum miR-126 expression without increasing the occurrence of ADR. |
| 期刊： | 2018年第29卷第4期 |
| 作者： | 谈晓娅，童强 |
| AUTHORS： | TAN Xiaoya，TONG Qiang |
| 关键字： | 格列美脲；二甲双胍； 2型糖尿病；血糖；血脂；胰岛功能；微核糖核酸-126 |
| KEYWORDS： | Glimepiride； Metformin； Type 2 diabetes； Blood glucose； Blood lipid； Islet function； miR-126 |
| 阅读数： | 354 次 |
| 本月下载数： | 6 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
